La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cardio Diagnostics Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cardio Diagnostics Hldgs..

Cardio Diagnostics Hldgs (NASDAQ:CDIO) Azioni, Catena delle Opzioni

Cardio Diagnostics Hldgs

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc. - Warrant

Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.09 by 155.56 percent. This is a 32.35 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $66.17 million which beat the analyst consensus estimate of $65.06 million by 1.71 percent. This is a 8.13 percent increase over sales of $61.19 million the same period last year.

Earnings

Earnings Beats

News

Vitesse Energy Q1 Adj. EPS $0.23 Beats $0.09 Estimate, Sales $66.17M Beat $65.06M Estimate

SIBN

SI-BONE Q1 EPS $(0.15) Beats $(0.23) Estimate, Sales $47.30M Beat $45.17M Estimate

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 percent. This is a 8.89 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.04 billion by 2.31 percent. This is a 0.49 percent increase over sales of $1.01 billion the same period last year.

Earnings Misses

V2X Q1 Adj. EPS $0.98 Beats $0.93 Estimate, Sales $1.02B Miss $1.04B Estimate

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) raises FY2025 FFO guidance from $4.59-$4.66 to $4.68-$4.73 vs $4.65 analyst estimate..

Guidance

National Health Investors Raises FY2025 Normalized FFO Guidance from $4.59-$4.66 To $4.68-$4.73 vs $4.65 Est

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $0.28 by 300 percent. This is a 36.59 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $133.11 million which beat the analyst consensus estimate of $121.06 million by 9.95 percent. This is a 11.88 percent increase over sales of $118.98 million the same period last year.

Limbach Holdings Q1 Adj. EPS $1.12 Beats $0.28 Estimate, Sales $133.11M Beat $121.06M Estimate

Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) affirms FY2025 Adj EPS guidance from $0.70-$0.90 to $0.70-$0.90 vs $0.78 analyst estimate. Affirms FY2025 sales outlook from $1.85 billion-$1.95 billion to $1.85 billion-$1.95 billion vs $1.88 billion estimate.

AMRC

Ameresco Affirms FY2025 Adj EPS Guidance of $0.70-$0.90 vs $0.78 Est; Affirms FY2025 Sales Guidance of $1.85B-$1.95B vs $1.88B Est

JRVR

James River Gr Hldgs Q1 Adj. EPS $0.19 Misses $0.27 Estimate, Sales $151.90M Miss $184.15M Estimate

EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.32 by 34.38 percent. This is a 320 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $166.63 million which beat the analyst consensus estimate of $158.08 million by 5.41 percent. This is a 82.98 percent increase over sales of $91.06 million the same period last year.

EVER

EverQuote Q1 EPS $0.21 Misses $0.32 Estimate, Sales $166.63M Beat $158.08M Estimate

TPIC

TPI Composites Changes Q1 Earnings Release Date From May 8, 2025 To May 12, 2025

Expected to complement Castle's current gastroenterology franchise
Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development
FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.

CSTL

Castle Biosciences Signs Definitive Agreement To Acquire Capsulomics; Terms Not Disclosed

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) raises FY2025 FFO guidance from $4.59-$4.66 to $4.64-$4.70 vs $4.65 analyst estimate..

National Health Investors Raises FY2025 FFO Guidance from $4.59-$4.66 to $4.64-$4.70 vs $4.65 Est

Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) raises FY2025 sales outlook from $280.00 million-$295.00 million to $287.00 million-$297.00 million vs $289.17 million estimate.

Castle Biosciences Raises FY2025 Sales Guidance from $280.00M-$295.00M to $287.00M-$297.00M vs $289.17M Est

AORT

Artivion Raises FY2025 Sales Guidance from $420.00M-$435.00M to $423.00M-$435.00M vs $423.64M Est

Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) raises FY2025 sales outlook from $1.04 billion-$1.06 billion to $1.07 billion-$1.09 billion vs $1.07 billion estimate.

Paymentus Holdings Raises FY2025 Sales Guidance from $1.04B-$1.06B to $1.07B-$1.09B vs $1.07B Est

BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.75 by 21.33 percent. This is a 19.74 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $682.26 million which beat the analyst consensus estimate of $644.46 million by 5.87 percent. This is a 12.97 percent increase over sales of $603.93 million the same period last year.

BWXT

BWX Technologies Q1 Adj. EPS $0.91 Beats $0.75 Estimate, Sales $682.26M Beat $644.46M Estimate

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.13 by 1.77 percent. This is a 2.68 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $89.30 million which beat the analyst consensus estimate of $84.76 million by 5.36 percent. This is a 9.55 percent increase over sales of $81.51 million the same period last year.

National Health Investors Q1 FFO $1.15 Beats $1.13 Estimate, Sales $89.30M Beat $84.76M Estimate

Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) sees Q2 sales of $255.000 million-$260.000 million vs $254.65 million analyst estimate.

Paymentus Holdings Sees Q2 Sales $255.000M-$260.000M vs $254.65M Est

Artivion Q1 Adj. EPS $0.06 Beats $(0.12) Estimate, Sales $98.98M Beat $94.99M Estimate

OMAHA, Neb. — Warren Buffett, CEO of Berkshire Hathaway, remains bullish on the long run. At the same time, he acknowledges that people will continue to be distracted by short-term market moves, which will continue to be unpredictable.
"The long-term trend is up," Buffett said at Berkshire's annual shareholders meeting on Saturday.
"Nobody knows what the market is going to do tomorrow, next week, next month," he added. "But they spend all their time talking about it, because it&#8217;s easy to talk about. But it has no value."
Buffett was responding to a shareholder's question about Berkshire's massive cash pile, which grew to&nbsp;<a href="https://www.bloomberg.com/news/articles/2025-05-03/buffett-s-berkshire-boosts-cash-hoard-to-record-347-7-billion">$347 billion in Q1</a>. He reiterated what he&nbsp;<a href="https://www.tker.co/p/warren-buffett-berkshire-hathaway-letter-2024">said in his annual letter</a>, which was that his preference is not to be sitting in so much cash. But he made clear that holding cash was smarter than making brash acquisitions.
"We would rather have conditions that have developed where we would have like $50 billion or something like that," he said. "But that just isn't the way the business works."
Buffett explained if he acquired businesses or accumulated stock solely for the sake of getting that cash pile down to $50 billion, "That would be the dumbest thing in the world to invest in that manner."
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa7ced383-6874-4803-9ec3-df43d204a91f_900x694.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa7ced383-6874-4803-9ec3-df43d204a91f_900x694.png" alt="" /></a><figcaption class="wp-element-caption">A hat with Warren Buffett's likeness sold by Justin's Boots at Berkshire Hathaway's annual meeting. (Source: Sam Ro)</figcaption></figure>
For now, Buffett believes it's better to keep dry powder for when Berkshire could be "bombarded with offerings" that offer better risk-reward opportunities than what he's seeing today.
"We have made a lot of money by not wanting to be fully invested at all times," he said.
Of course, this strategy is not for everyone. Buffett and Berkshire are in the business of acquiring companies and picking stocks. In fact,&nbsp;<a href="https://www.tker.co/p/stealth-bear-market-sp500-index-fund-performance">Buffett has historically recommended</a>&nbsp;most people to invest in passively managed S&amp;P 500 index funds.
"We don't think it's improper for people who are passive investors to just make a few simple investments and sit for their life in them," he said. "But we've made the decision to be in this business. So we think we can do a little better than that."
<h2 class="wp-block-heading">Buffett downplays recent market volatility, warns of a ‘hair curler' event &#x1f4c9;</h2>
A shareholder asked Buffett specifically about the&nbsp;<a href="https://www.tker.co/p/stock-market-charts-april-2025">market swings we experienced</a>&nbsp;in the past month.
"What has happened in the last 30, 45 days, 100 days … it's really nothing," he said. "This is not a huge move. … This has not been a dramatic bear market or anything of the sort."
Indeed,&nbsp;<a href="https://www.tker.co/i/42137695/you-can-get-smoked-in-the-short-term">you can get smoked in the short-term</a>. It's one of the&nbsp;<a href="https://www.tker.co/p/stock-market-historical-facts">truths about the stock market</a>.
"If it makes a difference to you whether your stocks are down 15% or not, you need to get a somewhat different investment philosophy," Buffett said. "The world is not going to adapt to you. You're going to have to adapt to the world."
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdf7cad13-6f3a-4a9f-891c-231371fe053c_896x711.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdf7cad13-6f3a-4a9f-891c-231371fe053c_896x711.png" alt="" /></a><figcaption class="wp-element-caption">A cutout of Warren Buffett promoting See's Candies. (Source: Sam Ro)</figcaption></figure>
Buffett cautioned that just because he doesn't think the recent market swings were notable doesn't mean we won't get a more violent downturn some time in the future. He said "certainly in the next 20 years" we will get a "hair curler" event.
"The world makes big, big, big mistakes, and surprises happen in dramatic ways," he said. "The more sophisticated the system gets, the more the surprises can be out of right field. That's part of the stock market. That's what makes it a good place to focus your efforts if you have the proper temperament for it — and a terrible place to get involved if you get frightened by markets that decline and get excited when stock markets go up. I don't mean to sound particularly critical. People have emotions. But you have to check them at the door when you invest.&#8221;
<h2 class="wp-block-heading">Zooming out &#x1f52d;</h2>
Buffett covered a lot during his five-hour long Q&amp;A. His comments on protectionist trade policy and pessimism toward the U.S. economy were particularly interesting. A lot of media outlets are covering it. I may write about it later.
But the big news out of this year's event was Buffett's announcement that he intends to step down as CEO as he makes way for vice chairman Greg Abel to succeed him.
"I think the time has arrived where Greg should become the chief executive officer of the company at year-end," Buffett said.
Buffett's time at the helm of Berkshire may be coming to an end. But his timeless investing lessons will surely endure.
&#x2A;&#x2A;

Equities

Long Ideas

Broad U.S. Equity ETFs

Global

Opinion

Success Stories

Markets

ETFs

General

Warren Buffett: "The Long-term Trend Is Up"

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.19 by 5.04 percent. This is a 20.19 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $3.77 billion which missed the analyst consensus estimate of $4.17 billion by 9.55 percent. This is a 4.36 percent decrease over sales of $3.94 billion the same period last year.

AECOM Q2 Adj. EPS $1.25 Beats $1.19 Estimate, Sales $3.77B Miss $4.17B Estimate

Press Releases

Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

BIAF

CDIO

CSDX

INBS

SOBR

TRIB

ABVC BioPharma

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioVie

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Curis

CEL-SCI

Elevation Oncology

GlycoMimetics

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Longeveron

Leap Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Nanoviricides

Ovid Therapeutics

Passage Bio

Portage Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Q32 Bio

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

X4 Pharmaceuticals

Benchmark

Northland Capital Markets

Screenshot 2024-09-16 at 6.26.11 PM

Biotech

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics&#39; Heart Disease Tests

Screenshot 2024-05-23 at 10.15.30 PM

Interview

This Medtech Company Is Bringing &#34;Precision&#34; Medicine To Cardiovascular Diagnostics

Screenshot 2024-05-06 at 5.31.30 PM

New Study Shows Cardio Diagnostics&#39; (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Screenshot 2024-04-30 at 5.36.02 PM

Health Care

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-04-23 at 6.35.19 PM

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Screenshot 2024-04-11 at 5.31.26 PM

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Comments

Cardio Diagnostics Hldgs

Cardio Diagnostics Hldgs (CDIO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO